Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, by Drug Type (Buphenyl, Ravicti, Ammonul, and Others), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jan 2023

Code : CMI5514

Pages :457

Formats :

Excel and PDF

Industry : Pharmaceutical

Regional Analysis

Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market- Regional Analysis

Among regions, North America is expected to dominate the market over the forecast period, owing to North America’s 36.1% market share in 2023 and increasing product approvals for the treatment of Ornithine Transcarbamylase (OTC) deficiency, which is expected to drive the global Ornithine Transcarbamylase (OTC) deficiency treatment market growth in the region. For instance, in August 2022, iECURE, a gene editing company focused on developing therapies that utilizes mutation-agnostic in- vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, announced that the U.S. Food and Drug Administration (FDA) had granted Rare Pediatric Disease Designation to its lead product candidate, GTP-506, for the treatment of Ornithine Transcarbamylase (OTC) deficiency, a rare genetic condition that can lead to irreversible neurological impairment, seizures, coma, and death, in pediatric population.

Europe is expected to be second largest region in global Ornithine Transcarbamylase (OTC) deficiency treatment market over the forecast period due to increasing research and development activities by key players in the region. For instance, in October 2021, Boehringer Ingelheim, a research-driven biopharmaceutical company, and Thoeris GmbH, a developer of therapeutic interventions intended for treating orphan diseases, announced a collaboration and license agreement with the aim to investigate novel first-in-class therapies for patients with urea cycle disorders (UCDs). UCDs are rare diseases caused by genetic liver dysfunctions, leading to excess ammonia levels in the blood and there is insufficient treatment available for this disease till date.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa